Otsuka Pharmaceutical Company, Limited

Sitryx Therapeutics Limited

Pharminox Limited

Cancer Research Technology Limited

Astex Therapeutics Limited

Cellcentric Limited

Step Pharma S.a.s.

Enyo Pharma

David Cousin

Stuart Thomas Onions

Steven Howard

Charlotte Mary Griffiths-Jones

Michael Liam Cooke

Christopher William Murray

Valerio Berdini

Ildiko Maria Buck

Alison Jo-Anne Woolford

Thomas Daniel Heightman

Stephen Thom

Peter J Machin

Jonathan Shannon

James Edward Harvey Day

David Norton

John Paul Watts

Marc O'Reilly

Malcolm Francis Graham Stevens

Andrew Richard Novak

Matthew Colin Thor Fyfe

David Michel Adrien Taddei

Kim Louise Hirst

Jeremy Peter Scott

James Daniel Osborne

Lorna Duffy

Jeffrey David St Denis

Benoît De Chassey

Geraint Jones

Pascal George

Eric Meldrum

Marc Geoffery Hummersone

Richard James Brown

Joseph William Wrigglesworth

Brian Christopher Bishop

Neil Anthony Pegg

Louise Birch

Steven Douglas Hiscock

Anil Patel

Oscar Barba

Darren James Dixon

Abdul Quddus

Saleh Ahmed

Jonas Calleja Priede

Matthew James Gaunt

Meenakshi Sundaram Shanmugham

David Parry-Jones

Aaron Michael Dumas

Peter Richard Mullens

Emma Blackham

David Kenneth Mycock

Sharon Jennings

Andrew James McCarroll

John Gareth Williams

Jihong Zhang

Alan Richard Burns

Elli Chatzopoulou

Jennifer Thomas

Gianna Toschi

Thomas Michael Waugh

Barry John Teobald

Eric Sing Yuen Tse

Alessio De Simone

Jonathan Martin Shannon

The invention relates to a compound of formula (Ia): and related aspects.

Phthalazine derivatives as pyruvate kinase modulators

The invention relates to compounds of formula (IW-1) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: wherein R, R, Rand Rare as defined herein.

Itaconic acid derivatives and uses thereof intreating an inflammatory disease or a disease associated with an undesirable immune response

The invention provides a compound of formula (0): The compounds are inhibitors of ERK1/2 kinases and will be useful in the treatment of ERK1/2-mediated conditions. The compounds are therefore useful in therapy, in particular in the treatment of cancer.

Benzolactam compounds as protein kinase inhibitors

Compounds of formula (I): (I) and related aspects. 

Aminothiazole compounds as inhibitors of CTPS1

The invention relates to processes for preparing isoindolin-1-one derivatives, and in particular processes for preparing (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid. The invention also relates to crystalline forms of the compound (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid and its salts.

Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them

The invention provides a compound of formula (0):  The compounds are inhibitors of ERK1/2 kinases and will be useful in the treatment of ERK1/2-mediated conditions. The compounds are therefore useful in therapy, in particular in the treatment of cancer.

A compound which is a benzimidazolyl isoxazole of formula (I): wherein: Rand R, which are the same or different, are each H or Calkyl; R, Rand R, which are the same or different, are each H or F; X is -(alk-, -alk-C(&#x2550;O)&#x2014;NR&#x2014;, -alk-NR&#x2014;C(&#x2550;O)&#x2014; or -alk-C(&#x2550;O)&#x2014;; Ris selected from &#x2014;S(&#x2550;O)R'; a 4- to 6-membered, C-linked heterocyclic group which is unsubstituted or substituted; and an N-linked spiro group of the following formula: Rand R, which are the same or different, are each H or Calkyl, or Rand Rform, together with the C atom to which they are attached, a Ccycloalkyl group; Rand R, which are the same or different, are each H, Calkyl, OH or F; Ris phenyl or a 5- to 12-membered, N-containing heteroaryl group and is unsubstituted or substituted; alk is Calkylene; R&#x2032; is Calkyl; and n is 0 or 1; or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer. 

Isoxazolyl substituted benzimidazoles

The present invention pertains generally to the field of therapeutic compounds, and more specifically to 3-substituted-8-substituted-3H-imidazo[5,1-d][1,2,3,5]tetrazin-4-one compounds of the following formula, wherein -A and &#x2014;B are as defined herein (collectively referred to herein as 38TM compounds):  The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit cell proliferation, and in the treatment of proliferative disorders such as cancer, etc., and methods of preparing such compounds.

3-substituted-8-substituted-3H-imidazo[5,1-d][1,2,3,5]tetrazin-4-one compounds and their use

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide (collectively referred to herein as 3TM compounds). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit cell proliferation, and in the treatment of proliferative disorders such as cancer, etc., and methods of preparing such compounds.

3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5-tetrazine-8-carboxylic acid amides and their use

Growing community of inventors

Nottingham, United Kingdom

David Cousin